Baltimore’s litigation against opioid companies has been wildly successful. Now comes the hard part of spending the money.
Over the twelve months to September 2024, McKesson recorded an accrual ratio of -1.99. That implies it has very good cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback